-- Scott Roberts
FRIDAY, Feb. 4 (HealthDay News) -- Makena (hydroxyprogesterone
caproate) has been approved by the U.S. Food and Drug
Administration to help prevent birth before 37 weeks of pregnancy
in women who have had at least one prior early delivery.
Makena, however, is not intended for women who are at
greater-than-average risk for preterm birth because they are
pregnant with multiple fetuses, the agency said Friday in a news
The drug was sanctioned under an accelerated-approval program
that requires post-marketing studies that provide additional proof
of the medication's benefit, the FDA said.
Makena is designed to be injected into the hip once weekly by a
health-care provider, beginning at 16 weeks and no later than 21
weeks of pregnancy.
In clinical testing involving 463 women aged 16 to 43, 37
percent of those who took Makena delivered early, compared with 55
percent among those who didn't take the drug, the FDA said.
The most common side effects were injection site reactions,
hives, nausea and diarrhea, the FDA said.
Makena is manufactured by Hologic Inc., of Bedford, Mass.
The U.S. Centers for Disease Control and Prevention has more
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.